

State of Oklahoma SoonerSelect > 4actna **SoonerCare**





Erwinaze® (Asparaginase Erwinia Chrysanthemi) and Rylaze™ [Asparaginase Erwinia Chrysanthemi (Recombinant)-rywn] **Prior Authorization Form**

Member Name:	Date of Birth:	Member ID#:	
	Drug Information		
□Physician billing (HCPCS code:) □Pharmacy b) □Pharmacy billing (NDC:)	
Dose: Regimen:	Start Date (or date of next dose):		
	Billing Provider Inform	nation	
Provider NPI:	der NPI: Provider Name:		
Provider Phone: Provider Fax:			
	Prescriber Informat	ion	
Prescriber NPI:	Prescriber Name:		
Prescriber Phone:	Prescriber Fax:	Specialty:	
Criteria Cri			
Yes No B. Does the member have asparaginase? Yes Lymphoblastic Lymphoma A. Will Erwinaze® or Rylaze Yes No B. Does the member have asparaginase? Yes	e [™] be used as a component a documented hypersensitiv No e [™] be used as a component a documented hypersensitiv No No ove, please indicate diagn	t of multi-agent chemotherapy? rity to Escherichia coli-derived t of multi-agent chemotherapy? rity to Escherichia coli-derived osis:	
For Continued Authorization: 1. Date of last dose: 2. Does member have any evidence Yes No 3. Has the member experienced ad Yes No If yes, please specify adverse reaction Prescriber Signature: Light that the indicated treatments	lverse drug reactions related	to Erwinaze [®] or Rylaze™ therapy?	

Fax completed prior authorization request form to 888-601-8461 or submit Electronic Prior Authorization through CoverMyMeds® or SureScripts. All requested data must be provided. Incomplete forms or forms without the chart notes will be returned. Pharmacy Coverage Guidelines are available at

AetnaBetterHealth.com/Oklahoma.

CONFIDENTIALITY NOTICE

This document, including any attachments, contains information which is confidential or privileged. If you are not the intended recipient, be aware that any disclosure, copying, distribution, or use of the contents of this information is prohibited. If you have received this document in error, please notify the sender immediately by telephone to arrange for the return of the transmitted documents or to verify their destruction.

Pharm - 207 7/28/2022